CAI logo

Caris Life Sciences, Inc.

CAI
Healthcare|Biotechnology|US
$25.23
-0.80 (-3.07%)
Tangible Book / Share
$2.18
Graham Number
$4.14
Cash / Share
$2.70

About

Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.

Stock Price

+2.5%(1Y)
1M
-8.3%
3M
+10.9%
6M
+56.2%
YTD
-6.5%
1Y
+1.7%
3Y
-9.9%
5Y
-9.9%

Pipeline Summary

4 total trials
0
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
Withdrawn: 1Recruiting: 1Terminated: 1Unknown: 1

Active Trials (1)

Metastatic Breast Cancer in Austria
NCT03870620Breast Cancer
Recruiting
Enrollment: 5,000 participants

Key Facts

Market Cap$7.13B
Employees1,846
CEODavid Dean Halbert
IPO DateJun 18, 2025
Beta0.70
52-Week Range$14.19 – $36.5
Avg Volume4,586,295
ExchangeNASDAQ

Ownership

Float4.0%
Shares Outstanding282.6M

Recent Insider Trades

Denton John RusselSELL
Sep 22, 20267,500 shares @ $31.82
Brille Brian JOPTION EX.
Sep 17, 2026400,000 shares @ $2.44
Brille Brian JOPTION EX.
Sep 17, 2026400,000 shares @ $2.44
Brille Brian JSELL
Sep 17, 2026400,000 shares @ $30.33
Spetzler David BaxleyOPTION EX.
Sep 3, 20261,000,000 shares @ $2.44

Peers

ADPTAdaptive Biotechnologies Corporation
$4.47B
BIAFbioAffinity Technologies, Inc.
$17.1M
CSTLCastle Biosciences, Inc.
$993.5M
IMDXInsight Molecular Diagnostics Inc.
$81.5M
NEONeoGenomics, Inc.
$2.18B
PSNLPersonalis, Inc.
$1.71B
WGSGeneDx Holdings Corp.
$1.86B
Data last updated: Nov 9, 2026, 04:00 AM